Israel Englander’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-8,600
| Closed | -$346K | – | 5828 |
|
|
2026
Q1 | $346K | Buy |
+8,600
| New | +$185K | ﹤0.01% | 4943 |
|
|
2024
Q4 | – | Sell |
-7,800
| Closed | -$225K | – | 5926 |
|
|
2024
Q3 | $225K | Sell |
7,800
-4,300
| -36% | -$159K | ﹤0.01% | 5374 |
|
|
2024
Q2 | $464K | Sell |
12,100
-57,400
| -83% | -$2.6M | ﹤0.01% | 4641 |
|
|
2024
Q1 | $4.09M | Buy |
69,500
+46,600
| +203% | +$2.97M | ﹤0.01% | 3081 |
|
|
2023
Q4 | $1.37M | Sell |
22,900
-80,500
| -78% | -$4.08M | ﹤0.01% | 3910 |
|
|
2023
Q3 | $3.93M | Buy |
103,400
+79,200
| +327% | +$3.48M | ﹤0.01% | 2933 |
|
|
2023
Q2 | $2.2M | Buy |
+24,200
| New | +$2.09M | ﹤0.01% | 3394 |
|
|
2022
Q4 | – | Sell |
-80,000
| Closed | -$5.46M | – | 6551 |
|
|
2022
Q3 | $5.46M | Buy |
+80,000
| New | +$4.73M | ﹤0.01% | 2808 |
|
|
2021
Q4 | – | Sell |
-16,000
| Closed | -$527K | – | 6739 |
|
|
2021
Q3 | $527K | Buy |
+16,000
| New | +$899K | ﹤0.01% | 5298 |
|
|
2020
Q1 | – | Sell |
-108,800
| Closed | -$3.33M | – | 3811 |
|
|
2019
Q4 | $3.33M | Buy |
+108,800
| New | +$3.01M | ﹤0.01% | 2244 |
|
Other funds holding APLS
Israel Englander's APLS Position: Q2 2026 in Review
Israel Englander sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 2,256,802 shares — an estimated $90.8M sold.
Israel Englander first reported a position in APLS in Q2 2018 and held it in 30 quarters. The position peaked at $90.8M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Israel Englander reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Israel Englander sold 2,256,802 Apellis Pharmaceuticals shares in Q2 2026, an estimated $90.8M.
- Israel Englander first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 30 quarters.
- Israel Englander's Apellis Pharmaceuticals position peaked at $90.8M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.